— Viking Therapeutics Inc. (NASDAQ: VKTX) reported Q3 2019 loss of $0.08 per share, vs. a loss of $0.13 expected.
— Net loss amounted to $5.7 million compared to $6.6 million last year.
— R&D expenses were $5.3 million compared to $5.7 million in the year-ago quarter.
— General and administrative expenses were $2.2 million compared to $1.7 million last year.
— At quarter-end, the company had cash, cash equivalents and short-term investments of $288.1 million.
— VKTX shares gained 0.15% following the announcement.
Get access to timely and accurate verbatim transcripts that are published within hours of the event.
Most Popular
Thermo Fisher Scientific (TMO) Q4 earnings drop despite higher revenues
Thermo Fisher Scientific Inc. (NYSE: TMO) announced fourth-quarter 2022 financial results, reporting a double-digit fall in adjusted earnings and an increase in revenues. Fourth-quarter revenues increased 7% annually to $11.5
Altria Group (MO) Q4 2022 Earnings: Key financials and quarterly highlights
Altria Group Inc. (NYSE: MO) reported fourth quarter 2022 earnings results today. Net revenues decreased 2.3% year-over-year to $6.1 billion. Net earnings attributable to Altria increased 65.6% to $2.6 billion
AMD Earnings: Advanced Micro Devices Q4 revenue up 16%, profit drops
Semiconductor company Advanced Micro Devices, Inc. (NASDAQ: AMD) reported a decline in fourth-quarter earnings, despite an increase in revenues. Earnings, excluding special items, dropped to $0.69 per share in the
